Client Update

BioReference LABORATORIES | genpath
OPKO Health Companies

JUNE 2021

Test Name	Test Code	Effective Date
Allergen Fennel Seed, IgE	**5054**	**Immediately**

Due to changes at our reference laboratory, Testing for **Allergen Fennel Seed, IgE** has been discontinued with no alternate testing available.

COVID-19 Ab, Semi-Quant	**M084**	**July 5**

As of July 5, **COVID-19 Ab, Semi-Quant (M084)**, which measures IgG antibody to COVID-19, will no longer be available for general use. Please request test **COVID-19 Ab, Qual/Quant (M160)** as a replacement for M084. M160 measures total antibody, including IgG, and provides both a qualitative (detected/not-detected) value as well as a semi-quantitative value.

N. Gonorrhea, Ab., Serum	**1287**	**Immediately**

Due to changes at our reference laboratory, **Testing for N. Gonorrhea, Ab., Serum** has been discontinued with no alternate testing available.

REMINDER - Customer Satisfaction Survey	**N/A**	**Immediately**

We invite you to share your feedback and opinions by participating in our **2021 Customer Satisfaction Survey.** As a token of our appreciation for completing this survey, you will be entered into a drawing for the chance to win a one year subscription to Amazon Prime or Shipt Delivery. The drawing will be on Monday, August 2, 2021. Your entry will remain separate from your survey responses to protect your anonymity. Completing this survey should take you approximately 5 minutes. Thank you for your time and we wish you luck in the drawing. Please visit: **https://www.bioreference.com/customersurvey** to take the survey.

Note: Employees of BioReference and their relatives are not eligible to participate.

REMINDER - 21st Century Cures Act	**N/A**	**April 5**

As of April 5, 2021, the Information Blocking (IB) provisions 45 CFR Part 170 and 171 of the 21st Century Cures Act restricts healthcare providers, including laboratories, from exercising any form of IB, which is the practice of interfering with access, exchange or use of electronic health information (EHI). This includes the ability to intentionally delay the release of test results to patients (unless the delay meets the conditions of one or more exceptions.)

Therefore, BioReference Laboratories, Inc. and its subsidiaries and divisions (collectively BioReference) will not delay test results from being released to patients, including results for clinical and pathology test results, unless a request to delay test results falls within one of the narrow exceptions. All test results will be released to the patient in the BioReference Patient Portal at or about the same time the results are released to the ordering provider via InsightDx, EMR or other delivery method. Only patients with a BioReference Patient Portal account will automatically receive electronic test results. Patients without a BioReference Patient Portal account can sign up at **https://www.bioreference.com/patient-portal** or request their test results via phone or secure email through our Patient Portal support group, which can be reached at (888) 279-0967 or **Patientportal@bioreference.com**

For more information about the 21st Century Cures Act and IB, please visit **http://bit.ly/CuresIB**, and for more information about IB exceptions, please visit **http://bit.ly/IBexceptions**.

481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com